Alpha Cancer Technologies Overview

  • Year Founded
  • 2008

Year Founded

  • Status
  • Private

  • Employees
  • 8

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $3M

  • Investors
  • 4

Alpha Cancer Technologies General Information

Description

Developer of clinical-stage biologic drugs designed to treat immuno-oncology and autoimmune diseases. The company's proprietary drugs use recombinant human alpha-fetoprotein (AFP) to treat autoimmune disease indications and its targeted delivery platform together with chemotherapy is used to treat cancer, enabling healthcare practitioners to enhance the performance of chemotherapy at a lower dose without any damage to healthy cells.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • MaRs Centre - South Tower
  • 200-101 College Street
  • Toronto, Ontario M5G 1L7
  • Canada
+1 (416)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Vertical(s)
Corporate Office
  • MaRs Centre - South Tower
  • 200-101 College Street
  • Toronto, Ontario M5G 1L7
  • Canada
+1 (416)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Alpha Cancer Technologies Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Later Stage VC 08-Mar-2019 $3M Completed Clinical Trials - Phase 2
8. Later Stage VC 01-Jan-2019 Completed Clinical Trials - Phase 2
7. Later Stage VC Completed Clinical Trials - Phase 2
6. Later Stage VC 17-Aug-2018 Completed Clinical Trials - Phase 2
5. Later Stage VC 01-Dec-2017 Completed Clinical Trials - Phase 1
4. Later Stage VC 15-Oct-2015 Completed Clinical Trials - Phase 1
3. Reverse Merger 18-Nov-2014 Cancelled Pre-Clinical Trials
2. Grant 28-Feb-2013 $3M $2.1M Completed Pre-Clinical Trials
1. Angel (individual) 01-Jan-2013 $2.1M $2.1M Completed Pre-Clinical Trials
To view Alpha Cancer Technologies’s complete valuation and funding history, request access »

Alpha Cancer Technologies Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of clinical-stage biologic drugs designed to treat immuno-oncology and autoimmune diseases. The company's prop
Drug Discovery
Toronto, Canada
8 As of 2018

South San Francisco, CA
 

Solna, Sweden
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Alpha Cancer Technologies Competitors (17)

One of Alpha Cancer Technologies’s 17 competitors is Genentech, a Formerly VC-backed company based in South San Francisco, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Genentech Formerly VC-backed South San Francisco, CA
Affibody Venture Capital-Backed Solna, Sweden
Nexoplex bio Formerly VC-backed Emeryville, CA
Fusion Pharmaceuticals Formerly VC-backed Hamilton, Canada
Replimune Formerly VC-backed Woburn, MA
You’re viewing 5 of 17 competitors. Get the full list »

Alpha Cancer Technologies Patents

Alpha Cancer Technologies Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2022313115-A1 Alpha-fetoprotein bioconjugates for disease treatment Inactive 23-Jul-2021
CA-3226570-A1 Alpha-fetoprotein bioconjugates for disease treatment Pending 23-Jul-2021
EP-4373844-A1 Alpha-fetoprotein bioconjugates for disease treatment Pending 23-Jul-2021
EP-4373844-A4 Alpha-fetoprotein bioconjugates for disease treatment Pending 23-Jul-2021
US-20250121075-A1 Alpha-fetoprotein bioconjugates for disease treatment Pending 23-Jul-2021 A61K47/64
To view Alpha Cancer Technologies’s complete patent history, request access »

Alpha Cancer Technologies Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Alpha Cancer Technologies Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
Bristol-Myers Squibb Corporation Minority
Innovation Grade Ventures Venture Capital Minority
Federal Economic Development Agency for Southern Ontario Government
Angel (individual) Minority
To view Alpha Cancer Technologies’s complete investors history, request access »

Alpha Cancer Technologies FAQs

  • When was Alpha Cancer Technologies founded?

    Alpha Cancer Technologies was founded in 2008.

  • Where is Alpha Cancer Technologies headquartered?

    Alpha Cancer Technologies is headquartered in Toronto, Canada.

  • What is the size of Alpha Cancer Technologies?

    Alpha Cancer Technologies has 8 total employees.

  • What industry is Alpha Cancer Technologies in?

    Alpha Cancer Technologies’s primary industry is Drug Discovery.

  • Is Alpha Cancer Technologies a private or public company?

    Alpha Cancer Technologies is a Private company.

  • What is the current valuation of Alpha Cancer Technologies?

    The current valuation of Alpha Cancer Technologies is .

  • What is Alpha Cancer Technologies’s current revenue?

    The current revenue for Alpha Cancer Technologies is .

  • How much funding has Alpha Cancer Technologies raised over time?

    Alpha Cancer Technologies has raised $36.5M.

  • Who are Alpha Cancer Technologies’s investors?

    Bristol-Myers Squibb, Innovation Grade Ventures, Federal Economic Development Agency for Southern Ontario, and have invested in Alpha Cancer Technologies.

  • Who are Alpha Cancer Technologies’s competitors?

    Genentech, Affibody, Nexoplex bio, Fusion Pharmaceuticals, and Replimune are some of the 17 competitors of Alpha Cancer Technologies.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process